Kornimate/medical-research-clean huggingface dataset:
survey of correction officers before and after a targeted education campaign

Conditions: Work-Related Condition

Summary: the investigators will implement a multifaceted target education campaign (tec) within the three jails about recognizing early psychotic symptoms and referring to the correctional health services. this campaign will include print materials and targeted trainings for correction officers. to develop all aspects of the tec, the investigators will convene a workgroup, meeting biweekly for the first 6 months, including the entire investigative team, as well as experts at the center for practice innovations (cpi). depending on the nature of agreed-upon educational materials, the investigators will use specific areas of expertise at cpi for development. materials will provide specific, actionable, and persuasive messaging about: (1) how to identify select signs of psychosis, (2) how to refer to the specialized early engagement support service (seess) (in year 2), and (3) the effectiveness of early treatment through coordinated specialty care for early psychosis. messaging will be continuous in the three jails.

because correction officers in the three jails of interest are critically positioned to influence pathways to care, print materials will be supplemented with professional outreach and education by the seess. roll-call is the approved venue by which all ongoing education happens for correction officers. roll-calls take place at the beginning of each shift (7am, 3pm, 11pm) every day of the week in the same location and last \~ 15 - 20 minutes; all staff starting that shift attend. during roll-call, brief messages (2-3 minutes) will be delivered by the controlling captains, which is the standard practice for communicating important information to correction officers. both daytime and overnight shifts will receive the targeted training for the 24 months of the tec. the investigators will collect pre-tec (baseline) and during-tec (at 6 months and 12 months) data from correction officers through brief surveys, which will be used to test changes in mean scores for knowledge, behavioral expectations, and self-efficacy, which are three key constructs from social cognitive theory.

Eligibility criteria:
inclusion criteria: * correction officers; * over the age of 21 exclusion criteria: * children under the age of 21 years

Keywords: correction officers
facial function reanimation by electrical pacing in unilateral facial paralysis.

Conditions: Facial Nerve Palsy

Summary: purpose of the trial is to study the activations of paralyzed facial muscles in a unilateral facial nerve palsy with a multi-channel electrical stimulator. the principle of the device is to measure muscle activity of the healthy side of the face by surface electromyography (emg) and to use this information to stimulate the corresponding muscles of the paralyzed side. the ultimate goal is to develop a prosthetic device for persons with a facial nerve palsy. the trial consists of several different studies. the studies' aims are 1. to study activations of paralyzed facial muscles by the electrical stimulation. 2. to study different stimulation pulse waveforms, frequencies, and electrode placement and their effect on the muscle activations and the tolerability of the stimulation. 3. to study whether a symmetrical movement on the paralyzed side can be achieved with electrical stimulation when compared to the movements of the healthy side. 4. to study tolerability of stimulation-elicited eye blink when watching a film and the effect of the stimulation-induced blink on the eye symptoms, the visual acuity, and the effects of the stimulation on the lacrimal fluid. 5. to develop a method for facial pacing, i.e. measuring the muscle activations on the healthy side of the face and to use this information to stimulate and activate the healthy side of the face. forty subjects with a chronic facial nerve palsy are recruited to the studies. each subject can participate in one or several studies. another forty subjects with an acute facial nerve palsy are recruited to the study on the tolerability and effect on the eye symptoms. additionally, altogether ninety healthy volunteers are recruited to the studies in order to gather preliminary information on the tolerability and the effects of the stimulations.


Eligibility criteria:
inclusion criteria: * a unilateral peripheral facial nerve palsy (patients) * willingness to participate (patients, healthy volunteers) exclusion criteria: * malignant diseases (a previously treated cancer is not an exclusion criterion) * unstable cardiovascular disease * severe immune deficiency * other severe neurological diseases (causing cognitive or physical impairment) * diabetic neuropathy

Keywords: facial nerve palsy facial paralysis functional electrical stimulation facial pacing
biologic characterization of patients with itp

Conditions: Immune Thrombocytopenia

Summary: this is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary itp patients. to this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation - for each line of therapy - and the results of the biological analysis performed at each time point will then be compared.

this is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view itp patients. patients with previously untreated primary itp who need first-line therapy will be included in the study. to this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation. the same assessments will be repeated in case of any potential new line of therapy. the results of the biological analysis performed at each time point will then be compared, in order to seek changes related to the natural history of the disease, the therapy administered and the response achieved.

Eligibility criteria:
inclusion criteria: 1. patients with primary itp, in need for first line treatment according to 2019 itp consensus2. 2. previously untreated patients. patients who have already started first-line therapy because of life-threatening bleeding are admitted to the study if samples are collected within 24 hours of starting treatment. in such cases, as first-line treatment steroids and platelet transfusions would be preferable over high-dose ivig. treatment received before the collection of samples will be carefully documented. 3. age ≥ 18 years 4. signed written informed consent according to ich/eu/gcp and national local laws. exclusion criteria: 1. secondary itp. patients with ana positivity without a diagnosis of sle are admitted to the study. as far as patients with itp and antiphospholipid antibodies positivity, those with triple positivity (anti-beta2glicoprotein antibodies, anti-cardiolipin antibodies, lupus anticoagulans positivity) are excluded.
clinical evaluation study of a device for detecting arteriovenous fistula vascular function

Conditions: Arteriovenous Fistula Flow Monitoring; Early Detection of Complications of Arteriovenous Fistula; Voiceprint

Summary: evaluation on the reliability, practicability and safety of a wearable device for measuring arteriovenous fistula function based on voice print.

arteriovenous fistula is the lifeline of maintenance hemodialysis patients. at present, there is a lack of a simple wearable real-time evaluation technology and device for arteriovenous fistula, which can help doctors find and deal with the complications of arteriovenous fistula timely and accurately. this study proposes an innovative design based on pvdf piezoelectric membrane by combining all kinds of technologies including nb-iot/4g transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels, so that the use time of arteriovenous fistula can be prolonged and the survival rate of dialysis patients can also be improved.

Eligibility criteria:
inclusion criteria: * age 18-75. * patients diagnosed with end-stage renal failure and planning to undergo venous fistula surgery or maintenance hemodialysis. * sign the informed consent. exclusion criteria: * pregnant and lactating women, bipolar disorder, schizophrenia and other serious mental illness. * other circumstances deemed inappropriate by the researcher * quit midway
the role of interactive binocular treatment system in amblyopia therapy

Conditions: Amblyopia

Summary: purpose: of determining the role of interactive binocular treatment (i-bittm) as a complementary method of patching in amblyopia therapy. materials and methods: in this randomized clinical trial study, 50 unilateral amblyopic children (25 male/25 female) less than 10 years with either best corrected visual acuity (bcva) ≤0.3 logmar (logarithm minimum angle of resolution) in amblyopic eye or difference of va≥2 lines between two eyes will be included. patients will be classified in the case and control groups (25 in each), randomly. patching will be recommended in both, cases will also received i-bittm. the child will be asked to play i-bittm games through glasses with conjugate colored filters. patching was continued for one month more in both groups. va and stereoacuity were measured at baseline, one month at the end of i-bittm treatment and one month after i-bittm treatment.

in this clinical trial study, our case group will receive i-bittm in the format of three playing games which have been designed suitable to the age of our cases. the mechanism of i-bittm has been designed in three playing games with inducing more foveal stimulation for the amblyopic eye through presentation of movable targets with more detailed. in addition, unmovable targets will presented to the non-amblyopic eyes. playing games were continued 30 minutes in each session for 5 days in each week within one month.

Eligibility criteria:
inclusion criteria: * bcva \<= 0.3 logmar exclusion criteria: * organic amblyopia * age less than 4 years * nystagmus

Keywords: amblyopia interaction binocular treatment (i-bittm) patch therapy
a study of bgm0504 in chinese patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to evaluate the efficacy and safety of bgm0504 in chinese patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * have been diagnosed with type 2 diabetes mellitus (t2dm); * glycosylated hemoglobin (hba1c) at screening/baseline: 7.0% ≤ hba1c ≤ 10%; * body mass index (bmi): 19.5 kg/m2 ≤ bmi ≤ 35.0 kg/m2; * fasting blood glucose (fpg) at screening/baseline: fpg ≤ 13.3 mmol/l exclusion criteria: * diagnosed with non-type 2 diabetes mellitus; * grade 3 hypoglycemia within 6 months prior to screening; * concomitant thyroid dysfunction that cannot be controlled at a stable drug dose at screening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy; * subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥ 160 mmhg and/or diastolic blood pressure ≥ 100 mmhg at screening) or untreated blood pressure meeting the above criteria at screening; * patients with a previous history or clinical evidence of acute or chronic pancreatitis; * malignant tumor confirmed within 5 years prior to screening (except cured carcinoma in situ) or potential malignant tumor assessed at screening; * patients with severe mental illness or language disorder at screening, unwilling or unable to fully understand and cooperate; * female subjects during pregnancy or lactation.
trial to evaluate efficacy and safety of apraglutide in sbs-if

Conditions: Short Bowel Syndrome

Summary: the primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

this is an international, multicenter, double-blind, randomized, placebo-controlled, trial to evaluate the efficacy and safety of weekly sc injections of apraglutide in adult subjects with sbs-if. the active pharmaceutical ingredient is apraglutide, a glp-2 analogue. the trial consists of a screening phase, a treatment phase of 48 weeks, and a safety follow-up phase. trial participants will receive, after successful screening, once weekly apraglutide.

Eligibility criteria:
inclusion criteria 1. signed informed consent for this trial prior to any trial specific assessment. 2. male and female subjects with sbs-if, receiving parenteral support (ps), secondary to surgical resection of the small intestine with either stoma or colon-in-continuity (cic). 3. subject must require ps at least 3 days per work and be considered stable. 4. no restorative surgery intended to change ps requirements in the trial period. 5. age ≥18 years at screening. exclusion criteria: 1. pregnancy or lactation. 2. major abdominal surgery in the last 6 months prior to screening. 3. history of cancer (including colon carcinoma) or clinically significant lymphoproliferative disease within ≤5 years, except for adequately treated basal cell skin cancer. 4. evidence of active inflammatory gi conditions in the previous 6 months. 5. evidence of decompensated heart failure. 6. evidence of severe renal or hepatic impairment. 7. any previous use of growth factors such as growth hormone (gh), native glp-2, glp-1, or glp-2 or glp-1 analogues should be discussed with the investigator.

Keywords: short bowel syndrome intestinal failure sbs sbs-if glp-2 short bowel syndrome intestinal failure
effect of artificial sweetener (afs) on glucose metabolism in patients with type 1 diabetes (t1d)

Conditions: Type 1 Diabetes (T1D); Healthy Subjects

Summary: the goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether non-nutritive sweeteners (nnss) are consumed simultaneously. we aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. our study will focus on patients diagnosed with type 1 diabetes (t1d) who are using an artificial pancreas (ap) system, as it allows us to monitor glucose and insulin levels over time. participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. they will then rate the sweetness of each beverage, and we will collect data from their ap system to monitor insulin and glucose level. to achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. insights gained from the pilot study will inform the main study. sucralose will be used as the nns, maltodextrin as the carbohydrate, and gymnema sylvestre (gs) as the sweet taste receptor blocker.


Eligibility criteria:
inclusion criteria: * participants with a diagnosis of t1d * hba1c ≤ 8 % * insulin pump therapy * adults of any gender or biological sex aged 18-45 years old, * body mass index (bmi) between 18.5-29.9 kg/m, * non-smokers, * english or french speaker. ●. who can consume chicken and fish exclusion criteria: * a major medical diagnosis that could potentially influence metabolic dysfunction * a major medical diagnosis other than t1d, * alcohol or substance use disorder, * eating disorder or history of malabsorptive syndrome, * inflammatory bowel disease, * self-reported impairment in taste or smell, * a known taste or smell dysfunction (e.g., anosmia), * active pregnancy and/or lactation, * food allergies or intolerances, * dislike of the test beverages, * history of bariatric surgery at any point in the past ●. regular consumer of gymnema sylvestre

Keywords: type 1 diabetes artificial pancreas artificial sweeteners non-nutritive sweeteners cross-over taste perception indirect calorimetry insulin glucose metabolism
oncotype dx in brca-mutated breast cancer patients: our experience. a retrospective observational monocentric study

Conditions: Breast Cancer; Genetic Predisposition

Summary: the study aims to evaluate the distribution of the oncotype dx rs® genomic test in patients with er-positive and her2-negative breast cancer treated from january 2012 to december 2021, focusing on patients presenting germline mutations.

in the past decades, genetic testing for cancer susceptibility has become essential in breast cancer (bc) management. up to 10% of bc cases are associated with an inherited mutation in various genes, especially brca 1 and brca 2. estrogen receptor (er) positivity is observed in 22% on brca 1 and 77% of brca 2 mutation carrier; moreover, other genes are strongly related to er-positive cancer. oncotype dx assay (genomic health, inc, redwood city, calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with er-positive and human epidermal growth factor 2 (her2)- negative bc; nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. according to oncotype dx recurrent score (rs)® a high rs shows a worse prognosis and predicts chemotherapy benefit in patients with er-positive her2-negative bc. combining oncotype dx rs® with other risk factor elements, in particular germline mutations, could help to select patients who would benefit from an appropriate adjuvant therapy. this retrospective observational study aims to evaluate oncotype dx rs® distribution in er-positive her2-negative bc patients treated from january 2012 to december 2021, focusing on patients harboring mutation in bc-associated genes compared to the general population.

Eligibility criteria:
inclusion criteria: * age at diagnosis at least 18 years * women who underwent breast surgery in osr * patients with er-positive, her2-unamplified early-stage bc who underwent the oncotype dx assay, according to the standard of care. exclusion criteria: * male * er negative or her2 amplified disease * patient s who did not undergo breast surgery in osr * patient s who did not undergo the oncotype dx assay

Keywords: brca1 brca2 genomic test
substrate ablation and remodelling in non-paroxysmal atrial fibrillation (af)

Conditions: Atrial Fibrillation

Summary: the investigators hypothesise that modification of the atrial fibrillation (af) substrate by radiofrequency ablation would improve single procedure success rates for radio frequency ablation (rfa) for non-paroxysmal af when compared to that achieved with short-term peri-procedural anti-arrhythmic drug therapy alone.


Eligibility criteria:
inclusion criteria: * ongoing symptoms (european heart rhythm association class 2 or above) in spite of treatment with rate control medication * non-paroxysmal atrial fibrillation, as pre-classified as * persistent af: af requiring electrical/ chemical cardioversion or that lasting \>7 days. these patients may be in af or in sinus rhythm at the time of their initial assessment and/ or at the time of their ablation. * continuous persistent af: these patients are persistently in af with or without antiarrhythmic drug therapy, as confirmed on a 24 hour holter. they may have undergone previous cardioversion(s). * sustained paroxysmal af with underlying substrate: patients with individual af episode(s) lasting \>12 hours but less than 7 days plus one or more of the following: * age \>65 years 21 * individual af episode(s) lasting \>24 hours * significant left atrial dilatation of \>45 mm on echo (parasternal long axis view) * obesity (body mass index \>30), and/ or history suggestive of sleep apnoea * diabetes mellitus requiring hypoglycaemic drugs and/or insulin exclusion criteria: * inability or unwillingness to receive oral anticoagulation with warfarin * previous ablation procedure for af * unwillingness or inability to complete the required follow up arrangements * presence of long standing persistent af with continuous af longer than 12 months. this includes patients in whom sinus rhythm may have been maintained following electrical cardioversion for a period of less than 1 week at a stretch. * documented typical atrial flutter * prior prosthetic mitral valve replacement or severe structural cardiac abnormality * contraindications and/ or prior intolerance to both amiodarone and flecainide. * reversible cause for atrial fibrillation * known hypertrophic or infiltrative cardiomyopathy
a study of hipec plus apatinib and s-1 conversion therapy for gastric cancer with positive exfoliative cancer cells

Conditions: Gastric Cancer

Summary: the purpose of this study is to investigate the efficacy and safety of hipec plus apatinib and s-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells


Eligibility criteria:
inclusion criteria: * 1. untreated (e.g. chemotherapy, radiotherapy and other antitumor therapy); 2. age:18 to 70 years old; 3. man or female (except pregnant and lactating women); 4. conﬁrmed to gastric adenocarcinoma; 5. proven gastric cancer of t stage was t3 and t4, and no distant metastasis was observed. the exfoliative cancer cells detection in peritoneal washes was positive; 6. blood cell count has to meet the following certeria: wbc≥3.5×109/l; anc≥1.5×109/l; plt≥100×109/l; hb≥90g/l; 7. liver/kidney function has to meet the following certeria: alt and ast≤2.5×uln tbil\<1.5×uln； serum creatinine ≤1.5×uln; 8. eastern cooperative oncology group (ecog) performance status of 0-1; 9. participants were willing to join in this study, good adherence and written informed consent. exclusion criteria: - 1. patients with other malignant tumors within 5 years; 2. metastasis was found to be visible to the naked eye; 3. it has serious or uncontrolled heart diseases and infections (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, poor-controlled hypertension and so on); 4. history of psychiatric drugs abuse and can't quit or patients with mental disorders; 5. patients with severe or uncontrollable mental illness; 6. patients with tendency of gastrointestinal bleeding, including the following: a local active ulcerative lesions, and defecate occult blood (+ +).has melena and hematemesis in two months; 7. pregnant or lactating women; 8. it have serious harm to the patient's safety or affect the patients who have completed the research. 9. the researchers think inappropriate.
safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sar442501 in pediatric participants with achondroplasia

Conditions: Osteochondrodysplasia

Summary: this is a phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of sar442501 in children from birth up to 12 years of age with achondroplasia.

up to approximately 275 weeks: 3 weeks screening + 52 weeks primary treatment period + up to approximately 216 weeks extended treatment period+ 4 weeks follow-up.

Eligibility criteria:
inclusion criteria: * participants must have ach with a confirmed mutation in the fgfr3 gene * participants and/or parent(s) or legal representative(s) must be willing and able to perform all the study procedures to the best of their physical ability. * parent(s) or legal representative(s) capable of giving signed informed consent and participants capable of giving assent when applicable. exclusion criteria: * have hypochondroplasia (or the n540k mutation) or short stature condition other than ach (eg, trisomy 21, pseudochondroplasia) * participants have received any dose of medications or investigational product, including human growth hormone, igf-1, intended to affect participants' stature or body proportions between the completion of obs16647 and enrollment (week 0/day 1/visit 2). * have a history of growth plate closure. * long bone fracture within 3 months of enrollment (week 0/day 1/visit 2) * current evidence of corneal or retinal disorder/keratopathy. * participants have had a previous surgical intervention involving the foramen magnum (stage 2 only). * hyperphosphatemia. the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.